Bayer

Bayer

German multinational pharmaceutical, chemical, and agricultural biotechnology company

Bayer is a publicly-traded, multinational company headquartered in Leverkusen, Germany. Founded over 150 years ago, its core competencies presently lie in the life science fields of health care and agriculture.

Business Areas

The company's life science unit has 3 main divisions, pharmaceuticals, consumer health, and crop science. It also has an animal health unit as well as a corporate functions business services unit. Also, Bayer has a 60% stake in Currenta, a company offering services for the chemical industry, including utility supply, waste management, infrastructure, safety, security, analytics, and vocational training.

Pharmaceuticals

In terms of sales, Bayer's pharmaceuticals segment is the largest in the company. The focus of this segment is primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology, and ophthalmology. Principal research centers are located in Germany, the United States, Finland, and Norway.

Consumer Health

The consumer health division focuses on everyday healthcare, where the company has a portfolio of over 170 brands to treat minor illnesses. The products are in areas such as digestive health, allergies, skin conditions, pain management, nutritional supplements, and common colds.

Crop Science

Bayer's crop sciences division focuses on delivering solutions to farmers in areas such as crop protection, seeds, and traits, and digital farming. In June 2018, Bayer completed its acquisition of Monsanto for approximately $63 billion. In connection with regulatory approval processes, the company agreed to divest portions of its businesses to BASF.

Animal Health

The company's animal health unit develops and markets products and solutions for the prevention and treatment of diseases in companion and farm animals. In November 2018, Bayer announced its plan to sell the unit, which is estimated to be worth up to €7 billion, along with several other brands. The move is estimated to result in about 12,000 job cuts worldwide.

Business Services

Bayer's business services unit is an in-house center for business solutions and business support process. Its portfolio ranges from the development and implementation of IT-based solutions and design, building, and execution of end-to-end process operations to in-house management consulting.

Bayer LifeHubs

Bayer's LifeHubs are co-working, learning, and incubation spaces managed by Bayer. They are intended to be used by startups and prospective startup companies as a space to collaborate, learn more about industries and industry-specific challenges, and as a general co-working and meeting space. They have locations in Boston, California, Lyon, Berlin, Singapore, Japan, and Reading.

CoLaborator

The Bayer CoLaborator program is a startup incubation program. They offer startups co-working spaces located within their LifeHubs and elsewhere. They focus on engagement between life-science startups and Bayer researchers. They have CoLaborator locations in Berlin, Kobe, Moscow, and San Francisco for pharmaceutical startups. They have a location in West Sacramento for crop science startups.

myAgro

Bayer has supported myAgro, a non-profit investing in and providing services for the development of smallholder farmers. Their initial focus was in Mali. Part of myAgro's work has been enabling farmers to save small amounts for seed and fertilizer through a cellphone for those unable to have a bank account. They also work on nutrition and hygiene seminars and deworming programs.

Leadership

Timeline

December 1, 2020
Bayer and Blackford Analysis announce AI Platform agreement in Radiology.
November 18, 2020
Bayer and BlockApps launch blockchain initiative TraceHarvest Network - Business Insider.

.

June 24, 2020
Bayer says it will pay up to US$10.9 billion to settle litigation over the subsidiary Monsanto's weedkiller Roundup, which has faced thousands of lawsuits over claims it causes cancer.
October 1, 2019
Bayer says it is to spend more than 25 billion euros ($27.22 billion) on research and development at its agriculture unit over the next 10 years.

August 7, 2019
Reuters reported last September initial plans by Bayer to divest its 60% stake in the chemical park operator, part of a string of assets it has put on the block to slash debt since its $63 billion takeover of Monsanto last year.
June 2019
Bayer announces that it is planning to invest $5.6 billion over the next 10 years in research on weed control.
March 25, 2019
Johnson & Johnson and Bayer agree to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell.
2018
Bayer acquires Monsanto for $63 billion.

Products

Product
Launch date
Industry
Website
Acceleron
97 Results
Results per page:
Page 1 of 4

People

Name
Role
LinkedIn

Amir Morani

Employee

Carmen Ionescu

Employee

Debra Lopez Quiat

Employee

Dr. Hartmut Klusik

Labor Director, Human Resources, Technology, & Sustainability

Heiko Schipper

President, Consumer Health Division

Kemal Malik

Innovation & Head of Latin America

Liam Condon

President, Crop Science Division & Animal Health Business Unit

Mary Kalnas

Employee

Stefan Oelrich

Head of Pharmaceuticals Division

Werner Baumann

Chairman & CEO

Wolfgang Nickl

CFO & Head of Asia Pacific and North America

Further reading

Title
Author
Link
Type
Date

Bayer Completes Monsanto Acquisition for $63 Billion

Web

Bayer to cut 12,000 jobs and sell brands

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

BlueRock Therapeutics

Emile F. Nuwaysir

Toronto

regenerative medicine

Casebia Therapeutics

Jim Burns

Cambridge, Massachusetts

gene-editing therapeutics

Joyn Bio

Michael Miille

Boston

probiotics for plants

News

Title
Author
Date
Publisher
Description
Yellow Wood Partners
February 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), ein in Boston ansässiges Private-Equity-Unternehmen, das sich auf Investitionen in Verbrauchermarken...
Fears Nachawati Law Firm
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- Bayer, the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement with cancer victims would end its massive...
Virendra Singh Rawat
February 24, 2021
@bsindia
A good number of prestigious first-time recruiters were also on-boarded this time apart from the legacy recruiters offering diverse job profiles
February 24, 2021
WebWire
Bayer is further strengthening its efforts to foster a more inclusive and diverse workforce and culture. By 2025, the company aspires to establish a 50/50 gender balance as an average across all combined management levels including lower and middle management (currently 40 percent women and 60 percent men). In the Group Leadership Circle (Top 540), which includes the Group Executive Circle (Top 75), the proportion of women is to be at least 33 percent by 2025 (currently 23 percent). By 203...
One Drop
January 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- One Drop, a leader in digital solutions for people living with diabetes and other chronic conditions, today announced that global partner,...
Ben Adams
January 13, 2021
FierceBiotech
German biotech CureVac shouldn't be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market.
Ben Adams
January 13, 2021
FierceBiotech
Welcome to Day 3 of the annual J.P. Morgan healthcare conference. Here's your need to know, as Bayer says CureVac is not just an also-ran in the mRNA COVID-19 vaccine race while Aridis' CEO says the pandemic has lamentably not secured more interest in antibiotic R&D.
The Associated Press
January 7, 2021
Coronavirus
A German company that is in the advanced stages of producing a vaccine against COVID-19 is linking up with pharmaceutical giant Bayer to help develop and distribute the product.
Ben Adams
January 6, 2021
FierceBiotech
Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences.
Jonathan Shieber
January 6, 2021
TechCrunch
Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences giant, Bayer. The company's technology uses new computational biological techniques to manufacture cell and gene therapies that can more precisely target specific [...]
WuXi Biologics
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -WuXi Biologics ("WuXi Bio") (2269.HK), ein weltweit tätiges Unternehmen mit einer Open-Access-Technologieplattform für Biologika, und Bayer haben...
WuXi Biologics
December 23, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics (« WuXi Bio ») (2269.HK), une entreprise mondiale disposant de plates-formes technologiques biologiques à accès libre de premier...
WuXi Biologics
December 21, 2020
www.prnewswire.com:443
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and Bayer, today announced an...
Press Trust of India
December 10, 2020
@bsindia
The company launches mini packs of hybrids vegetable seeds
Ben Adams
December 7, 2020
FierceBiotech
German pharma Bayer is moving into cell therapy R&D with its latest pact focusing on tough-to-treat lung cancers with Atara Biotherapeutics.
Nick Paul
December 2, 2020
FierceBiotech
Bayer has created a cell and gene therapy platform to support its growing pipeline of advanced therapy medicinal products. The platform is intended to enable Bayer to make its expertise and resources available to its partners while preserving their autonomy and culture.
Conor Hale
December 1, 2020
FierceBiotech
Bayer is strengthening its ties with Scottish artificial intelligence developer Blackford Analysis to build a one-stop shop for applications in medical imaging.
December 1, 2020
BioSpace
Bayer and Blackford Analysis Announce AI Platform Agreement in Radiology - read this article along with other careers information, tips and advice on BioSpace
Ben Adams
November 23, 2020
FierceBiotech
Big Pharma friend argenx has snapped up an FDA priority review voucher from Bayer for $98 million.
Rhea Patel
November 20, 2020
Business Insider
Bayer's G4A Digital Health Partnerships accelerator program will enable it to collaborate with five new startups from around the world.
SHOW MORE

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.